A portosystemic shunt bypasses liver detoxification, causing hepatic encephalopathy. Learn about bile acid testing, surgical options, and medical management outcomes.

A diagnosis of a portosystemic shunt (PSS)—commonly referred to as a liver shunt—is a high-stakes, stressful moment for any pet owner. This vascular abnormality can cause a wide range of troubling symptoms, from stunted growth and digestive upset to severe neurological signs like blindness, disorientation, and seizures.

Because a liver shunt fundamentally alters how a dog’s body processes nutrients and toxins, managing it requires making complex medical decisions. Owners must navigate diagnostic steps, stabilize their puppy with diet and medication, and weigh the costs, risks, and survival statistics of delicate vascular surgery against the limitations of lifelong medical management.

This comprehensive guide details the pathophysiology of liver shunts in dogs, how they are diagnosed, and the differences between congenital and acquired shunts. It also provides a detailed medical-versus-surgical decision framework, examines the specific postoperative complications you must watch for, and presents primary care data from VetCompass to highlight breed-specific risks.

The short answer, first

A portosystemic shunt (PSS) is an abnormal blood vessel that connects the portal vein (which drains blood from the stomach, intestines, pancreas, and spleen) directly to the systemic circulation. This allows gut blood to bypass the liver, preventing the organ from filtering toxins (such as ammonia) and extracting vital nutrients.

These unfiltered toxins build up in the bloodstream and cross the blood-brain barrier, causing a neurological syndrome called hepatic encephalopathy.

The clinical signs include stunted puppy growth, chronic vomiting or diarrhea, increased drinking and urinating (PU/PD), ammonium urate bladder stones, and neurological signs like head pressing, pacing, circling, temporary blindness, or seizures, which often worsen shortly after eating.

Gut Blood (with toxins like ammonia)
   │
   ├─► NORMAL PATHWAY ──────► Liver (Detoxification) ──► Systemic Circulation (Clean)
   │
   └─► SHUNT PATHWAY (PSS) ─► Bypasses Liver ──────────► Systemic Circulation (Toxic) ──► Brain (Encephalopathy)

Diagnosis starts with a blood chemistry panel showing low blood urea nitrogen (BUN), low albumin, and low cholesterol, combined with a pre- and post-prandial bile acids test showing high levels. It is confirmed by advanced imaging, with computed tomography (CT) angiography as the gold standard.

For a single congenital shunt, surgery is the treatment of choice. The surgeon applies a device (such as an ameroid constrictor or cellophane band) that gradually closes the shunt over several weeks.

Surgical prognosis is excellent: The perioperative survival rate is about 93% to 95% (mortality roughly 5–7% with ameroid constrictor attenuation), and 85% of dogs achieve complete clinical recovery within 4 months.
Medical management is stabilizing, not curative: It involves a moderately protein-restricted diet, lactulose to trap ammonia in the gut, and oral antibiotics to reduce ammonia-producing bacteria.
Medical-only outcomes are inferior to surgery: Diet, lactulose, and antibiotics can stabilize a dog for a time, but they do not stop the liver from continuing to shrink and fail. Dogs managed medically alone live substantially shorter lives than surgically treated dogs, and most eventually require surgery or are euthanized as the disease progresses.

Primary care data from the Royal Veterinary College VetCompass program confirms a strong genetic basis, showing a portosystemic shunt prevalence of 0.15% (5 of 3,308 Yorkshire Terriers) under primary care in the UK. Affected dogs should never be bred.

What is a portosystemic shunt, and how does it affect a dog?

In a healthy dog, the portal vascular system plays a vital role in metabolism. When a dog digests food, blood from the gastrointestinal tract—rich in absorbed nutrients, hormones, and toxins (specifically ammonia produced by gut bacteria)—is collected into the portal vein.

This vein leads directly into the liver, where the blood branches into tiny capillaries. The liver cells (hepatocytes) process these nutrients, store glycogen, synthesize proteins like albumin, and detoxify waste products.

Most notably, the liver converts toxic ammonia (a byproduct of protein metabolism) into urea, which is safely excreted by the kidneys into the urine.

When a portosystemic shunt is present, this filtering system is bypassed. An abnormal vessel connects the portal vein directly to the vena cava (the main vein returning blood to the heart) or the azygous vein.

As a result:

Toxins enter systemic circulation: Unfiltered blood enters the general circulation, carrying ammonia, mercaptans, and short-chain fatty acids throughout the body.
Hepatic Encephalopathy: High ammonia levels cross the blood-brain barrier, disrupting neurotransmitters and causing swelling in the brain cells (astrocytes). This leads to neurological dysfunction.
Hepatic Atrophy: The liver relies on trophic hormones (like insulin and hepatotrophic factors from the pancreas) to grow. Because it is deprived of portal blood flow, the liver remains small, undeveloped, and dysfunctional (hepatic atrophy).

Congenital vs. Acquired, Extrahepatic vs. Intrahepatic

Veterinarians classify shunts into two primary categories: congenital (present at birth) and acquired (developing later in life). Congenital shunts are further divided based on their anatomical location.

Portosystemic Shunt (PSS)
 ├── Congenital (Single vessel, present at birth)
 │     ├── Extrahepatic (Outside liver; small breeds like Yorkies)
 │     └── Intrahepatic (Inside liver; large breeds like Wolfhounds)
 └── Acquired (Multiple vessels, secondary to chronic portal hypertension)

1. Congenital Extrahepatic Shunts

Congenital extrahepatic shunts are single, abnormal vessels located outside the liver tissue. They represent approximately 70% to 80% of all congenital shunts and are overwhelmingly diagnosed in small and toy breeds.

The abnormal vessel typically connects the portal vein or one of its tributaries directly to the caudal vena cava or the azygous vein. Because these vessels are outside the liver, they are surgically accessible, making extrahepatic shunts good candidates for surgical correction.

2. Congenital Intrahepatic Shunts

Congenital intrahepatic shunts are single vessels located deep within the liver tissue. They account for about 20% to 30% of congenital cases and are primarily diagnosed in large and giant breeds.

During fetal development, blood bypasses the liver via a vessel called the ductus venosus. In healthy puppies, this vessel closes within three days of birth. If it fails to close, it remains as a patent ductus venosus (an intrahepatic shunt).

Because these vessels are buried inside the liver tissue, traditional open surgery is highly challenging. Intrahepatic shunts are typically managed using minimally invasive interventional radiology, such as placing metal coils inside the vessel via a catheter (coil embolization).

3. Acquired Shunts

Acquired shunts are completely different from congenital shunts. They are multiple, small collateral vessels that develop later in life.

When a dog develops severe, chronic liver disease (such as cirrhosis or liver failure), the liver tissue becomes scarred and fibrotic. This scarring obstructs blood flow, causing blood pressure inside the portal vein to rise (portal hypertension).

To relieve this pressure, the body opens dormant blood vessels, creating multiple bypasses. Acquired shunts are the body's safety valves.

Acquired shunts can never be treated with surgery. Closing these vessels would cause fatal portal hypertension. Treatment must focus on managing the underlying liver failure medically.

Breed Predisposition: The VetCompass Baseline

Congenital portosystemic shunts are highly heritable, meaning specific breeds carry a significant genetic risk.

To quantify this risk in a real-world primary care population, we can look at data from the Royal Veterinary College VetCompass program, which records the health outcomes of dogs under UK general-practice care. The published Yorkshire Terrier cohort includes 3,308 dogs.

Among this cohort, 5 dogs were confirmed to have a portosystemic shunt, establishing a breed-specific prevalence of 0.15% (1 in 660 Yorkies). This is a very high rate for a severe congenital disorder, confirming the Yorkshire Terrier as the primary poster breed for extrahepatic shunts.

Table: Breed Predispositions and Shunt Locations

Breed	Shunt Type	Typical Location	VetCompass / Published Risk Accent
Yorkshire Terrier	Congenital Extrahepatic	Portal vein to vena cava or azygous vein.	0.15% prevalence in VetCompass UK primary care. The highest-risk breed.
Maltese	Congenital Extrahepatic	Splenic or gastroduodenal vein bypass.	High risk; genetic studies show autosomal recessive inheritance patterns.
Miniature Schnauzer	Congenital Extrahepatic	Portocaval or portoazygous.	High risk; often presents with concurrent ammonium urate bladder stones.
Pug	Congenital Extrahepatic	Portoazygous.	Notable risk; often shows severe neurological signs.
Irish Wolfhound	Congenital Intrahepatic	Patent ductus venosus (inside liver).	High risk; inherited trait; screening puppies via bile acids is common.
Golden Retriever	Congenital Intrahepatic	Left divisional intrahepatic.	Moderate-high risk; typically diagnosed around 6–12 months of age.

Clinical Signs and Hepatic Encephalopathy

A dog with a liver shunt can present with a wide variety of symptoms, which can vary from day to day. Some dogs show severe signs as young puppies, while others with smaller shunts are not diagnosed until adulthood.

1. Neurological Signs (Hepatic Encephalopathy)

Hepatic encephalopathy (HE) is the hallmark of PSS. The signs are caused by neurotoxins (mainly ammonia) that cause brain swelling.

These signs typically worsen within 1 to 2 hours after a meal, as the digestion of protein releases a surge of ammonia into the bloodstream.

"Staring into space" or disorientation: The dog may appear to get stuck in corners, look dazed, or fail to respond to their name.
Pacing and circling: Compulsive, repetitive walking, often in one direction.
Head pressing: Physically pressing the top of the head against walls, furniture, or the floor. This is a clear sign of brain swelling and discomfort.
Temporary blindness: The eyes are normal, but the brain cannot process visual signals (cortical blindness).
Seizures & Coma: Severe brain swelling can trigger generalized seizures, which can progress to stupor or death.

2. Physical and Gastrointestinal Signs

Stunted growth: Puppies with shunts are often the "runt of the litter." They fail to gain weight and have poor muscle development because they cannot synthesize proteins effectively.
Poor coat quality: A thin, dry, scruffy coat, often due to chronic malnutrition.
Digestive issues: Chronic, intermittent vomiting, diarrhea, or loss of appetite.
Hypersalivation (drooling): Highly common in cats with shunts, but also seen in dogs.

3. Urinary Signs (Ammonium Urate Stones)

High levels of ammonia and uric acid are excreted by the kidneys into the urine. In the bladder, these compounds precipitate to form ammonium urate crystals and stones.

Ammonium urate stones are radiolucent, meaning they do not show up on standard X-rays and require ultrasound or contrast radiography to detect. If a male puppy presents with urinary obstruction or straining, a liver shunt must be ruled out.

The Diagnostic Pathway

Identifying a liver shunt requires a step-by-step diagnostic workup, starting with routine bloodwork and progressing to functional testing and advanced imaging.

Routine Bloodwork (Low BUN, low albumin, low cholesterol, microcytosis)
                    │
                    ▼
Bile Acids Testing (Pre- and post-prandial; highly elevated)
                    │
                    ▼
Fasting Blood Ammonia (Elevated; supports hepatic encephalopathy)
                    │
                    ▼
Abdominal Ultrasound (Screening; check liver size, look for extrahepatic vessels)
                    │
                    ▼
CT Angiography (Gold standard; maps the shunt vessel for the surgeon)

1. Routine Screening Bloodwork

Before running specialty tests, a standard Complete Blood Count (CBC) and Biochemistry Panel often show characteristic "red flags":

Low Blood Urea Nitrogen (BUN): The liver cannot convert ammonia into urea.
Low Albumin & Low Cholesterol: The liver is too small and dysfunctional to synthesize these vital proteins and fats.
Elevated Liver Enzymes (ALT, AST): Mild-to-moderate elevations, reflecting liver cell damage.
Microcytosis: Small red blood cells (low Mean Cell Volume), a classic finding in dogs with shunts, likely due to altered iron transport.

2. Pre- and Post-Prandial Bile Acids Testing

A bile acids test is the most common functional test for liver shunts. Bile acids are synthesized by the liver, stored in the gallbladder, and released into the intestines after a meal to help digest fats. They are then reabsorbed by the gut and returned to the liver via the portal vein (enterohepatic circulation).

To perform the test:

Draw a blood sample after a 12-hour fast (pre-prandial).
Feed the dog a small, fatty meal to stimulate the gallbladder to contract.
Draw a second blood sample exactly 2 hours after eating (post-prandial).

In a healthy dog, the liver rapidly extracts bile acids from the portal blood, keeping blood levels low.

In a dog with a liver shunt, the bile acids bypass the liver and enter systemic circulation. Bile acid values are typically highly elevated (often > 100 µmol/L) on both the pre- and post-prandial draws, indicating compromised liver function.

3. Advanced Diagnostic Imaging

While bloodwork indicates liver dysfunction, imaging is required to locate the shunt.

Abdominal Ultrasound: A highly useful, non-invasive screening tool. An experienced radiographer can often find the abnormal vessel, measure liver size, and check for bladder stones. However, ultrasound can miss small extrahepatic shunts or fail to distinguish intrahepatic vessels.
Portal Scintigraphy: A nuclear medicine test where a radioactive isotope is rectalized or injected into the spleen. A gamma camera tracks the path of the isotope; if it reaches the heart before the liver, a shunt is confirmed.
Computed Tomography (CT) Angiography: The absolute gold standard. A contrast agent is injected into a vein, and a rapid 3D CT scan maps the entire abdominal vasculature. It provides the surgeon with a precise map of the shunt vessel, its origin, its insertion, and the size of the portal vein.

How is a liver shunt managed medically before surgery?

Medical management is designed to reduce the production and absorption of neurotoxins (mainly ammonia) in the gastrointestinal tract, thereby controlling hepatic encephalopathy.

It is used to stabilize a puppy for 2 to 4 weeks before surgery, or as a lifelong treatment when surgery is not possible due to financial constraints, multiple acquired shunts, or high surgical risk.

Medical management sits on a three-legged stool. The medication doses mentioned below are standard reference ranges; a veterinarian must set the exact drug, dose, and schedule for each dog, because puppies with shunts have reduced liver function and clear some drugs abnormally slowly. Do not give these medications without veterinary direction.

1. Dietary Modification

Diet is the most important component of medical management. The goal is to minimize the amount of ammonia produced during digestion.

Moderate Protein Restriction: Feeding excessive protein increases ammonia levels. However, puppies need protein to grow, so severe restriction must be avoided. Protein should be highly digestible and high-quality.
Dairy and Vegetable Protein: Studies show that dogs with shunts tolerate dairy (like cottage cheese) and vegetable (soy or oatmeal) proteins much better than meat proteins.
Commercial Liver Diets: Diets like Hill's l/d or Royal Canin Hepatic are formulated with appropriate protein levels, high zinc (which supports ammonia detoxification), and restricted copper (to prevent liver storage).

2. Lactulose

Lactulose is a synthetic, non-absorbable sugar syrup. It is administered orally, typically 2 to 3 times daily, adjusted to produce 2 to 3 soft, formed stools per day.

Lactulose works via three mechanisms:

Acidifies the colon: Gut bacteria ferment lactulose, producing organic acids that lower the pH of the colon. This acidic environment converts ammonia ($NH_3$) into ammonium ($NH_4^+$). Ammonium is charged and cannot be absorbed across the intestinal wall, trapping it in the stool.
Osmotic laxative: It draws water into the colon, speeding up transit time and flushing out bacteria and toxins before they can be absorbed.
Reduces bacterial population: It alters the colon environment, making it less favorable for ammonia-producing bacteria.

3. Antibiotics

Oral antibiotics are used to reduce the population of urease-producing bacteria in the gut, thereby lowering ammonia production.

Neomycin: A non-absorbable aminoglycoside antibiotic. Because it remains in the gut and is not absorbed into the body, it has low systemic toxicity.
Metronidazole: Often used at a low dose (7.5 to 10 mg/kg twice daily). However, because metronidazole is cleared by the liver, dogs with shunts are prone to drug accumulation and metronidazole toxicity (which causes neurological signs like wobbliness and head tilt, mimicking hepatic encephalopathy).

Medical vs. surgical treatment: which is best for a liver shunt?

For a single congenital shunt, owners face a critical choice: proceed with surgery or manage the condition medically.

Why Surgery is the Best Choice

Congenital liver shunts are progressive. Deprived of portal blood flow, the liver undergoes progressive atrophy and fibrosis.

Over time, the remaining liver cells lose their ability to function, leading to chronic liver failure, persistent hepatic encephalopathy, and a poor quality of life.

Published clinical studies provide stark outcome comparisons:

Medical Management Only: Diet and lactulose can temporarily stabilize a dog's signs, but medical care alone does not stop progressive liver atrophy. A systematic review and meta-analysis (Serrano et al., JVIM 2019) concluded that surgical attenuation yields better clinical outcomes and longer survival than medical management. Lifelong medical management is typically reserved for dogs with multiple acquired shunts, where surgery is financially impossible, or while a dog is stabilized before surgery.
Surgical Attenuation: Surgery physically redirects blood flow back through the liver. This stimulates the liver cells to regenerate, allowing the liver to grow to a normal size and resume normal function. About 85% of dogs are clinically normal within 4 months of surgery, requiring no long-term medications or dietary restrictions.

Surgical Methods

Historically, surgeons tied off the shunt vessel completely using suture material (ligature). However, closing the vessel immediately caused a sudden, fatal buildup of blood pressure in the portal vein (portal hypertension). Modern surgery uses devices that close the shunt gradually over several weeks:

Ameroid Constrictor: A ring made of casein (a milk protein) encased in a stainless steel collar. The ring is placed around the shunt vessel. Casein absorbs abdominal fluid and swells slowly, while the body forms scar tissue around it. This gradually closes the vessel over 4 to 6 weeks, allowing the portal vein time to stretch and accommodate the increased blood flow.
Cellophane Banding: A strip of sterile cellophane is wrapped around the shunt vessel. The cellophane triggers a mild inflammatory reaction, causing the body to form scar tissue that gradually closes the vessel over several weeks.
Coil Embolization: For intrahepatic shunts. A veterinary radiologist passes a catheter through the jugular vein into the shunt vessel under fluoroscopy. They deploy metallic coils inside the vessel, which trigger blood clots to form, gradually blocking the shunt.

Postoperative Risks: Seizures and Portal Hypertension

While surgery offers a cure, the immediate postoperative period (the first 72 hours) carries significant risks. There are two major complications owners must understand:

1. Post-Attenuation Seizures

This is the most frustrating and poorly understood complication of liver shunt surgery, occurring in 5% to 20% of dogs after ameroid constrictor placement.

These seizures are different from hepatic encephalopathy. They typically occur 2 to 3 days after surgery, in a dog that is otherwise bright and alert. The seizures are often severe, progressing to status epilepticus (non-stop seizing), and carry a high mortality rate.

The Cause: Thought to be due to the sudden exposure of a "starved" brain to normal neurotransmitter levels, or changes in GABA receptors.
Prophylaxis is contested: The most-cited study (Fryer et al., JVIM 2011) found that levetiracetam (Keppra) at 20 mg/kg by mouth three times daily, started at least 24 hours before surgery, significantly reduced post-op seizures. However, a larger later study (Mullins et al., Veterinary Surgery 2019) found no reduction in seizure incidence with prophylactic levetiracetam. Because the evidence is mixed, levetiracetam prophylaxis is common but not universally adopted; the dose, start time, and duration are set by the surgical team for each dog.

2. Portal Hypertension

If the shunt closes too quickly, or if the portal vein is too small to handle the returned blood flow, pressure inside the portal vein rises rapidly.

Clinical Signs: Severe abdominal pain, bloody diarrhea, fluid accumulation in the abdomen (ascites), shock, and death.
Management: This is a medical emergency. If portal hypertension occurs, the dog must be hospitalized for aggressive support. In severe cases, the surgeon may need to return to the operating room to remove the ameroid constrictor.

Life Expectancy and Prognosis

The long-term outlook for a dog with a liver shunt depends heavily on whether they receive successful surgery.

Surgical Attenuation (Success): If the dog survives the immediate postoperative period and the shunt successfully closes, the prognosis is excellent. The liver will regenerate, and the dog can live a normal life span (12 to 15 years) with no dietary restrictions.
Persistent Shunting: In about 15% to 21% of cases, the shunt does not close completely, or a second "acquired" shunt develops. These dogs may require long-term medical management but still live longer and have a better quality of life than dogs managed medically from the start.
Medical Management Only: Survival is substantially shorter than with surgery, and most dogs eventually worsen as liver function declines — though some dogs with small shunts and strict dietary compliance remain stable for longer. Published median survival for medically managed dogs varies widely across studies.

Breeding Recommendations

Congenital portosystemic shunts are inherited. In Yorkshire Terriers, genetic studies have shown that the risk is polygenic, involving multiple genes.

Dogs diagnosed with a portosystemic shunt should never be bred. Furthermore, the parents (sires and dams) of an affected puppy should not be bred again to each other, as they are confirmed carriers of the genetic risk.

Frequently Asked Questions

What is the life expectancy of a dog with a portosystemic shunt? With medicine and diet alone, a dog can be stabilized for a time, but survival is substantially shorter than with surgery and most dogs eventually worsen as the liver continues to fail. However, if the dog undergoes successful surgery to close the shunt, the liver will regenerate, and they can live a normal, healthy life span (12 to 15 years).

Can a dog recover from a liver shunt without surgery? No. A liver shunt is a physical, structural blood vessel abnormality. It cannot be dissolved or cured with medication or diet. Medical management can temporarily control the symptoms of brain swelling, but the liver will continue to fail over time. Surgery is the only definitive cure.

What breeds are prone to portosystemic shunts? Yorkshire Terriers are the highest-risk breed, with VetCompass data showing a primary care prevalence of 0.15%. Other prone small breeds include Maltese, Havanese, Miniature Schnauzers, and Pugs (which get extrahepatic shunts). Large breeds like Irish Wolfhounds and Golden Retrievers are prone to intrahepatic shunts (inside the liver).

What are the signs a puppy might have a liver shunt? The most common signs are stunted growth (being the smallest of the litter), poor coat quality, and neurological signs that worsen after eating—such as staring at walls, pacing, circling, head pressing, temporary blindness, or seizures. Some puppies also develop bladder stones, causing straining or bloody urine.

Is liver shunt surgery risky, and how much does it cost? Liver shunt surgery is a delicate procedure that carries a 5% to 6% mortality rate. The primary risks are portal hypertension and severe seizures in the days immediately following surgery. In the US, the cost typically ranges from $3,000 to $8,000+, depending on whether the shunt is extrahepatic (cheaper) or intrahepatic (more expensive, requiring interventional radiology).

Sources

ACVS: Portosystemic Shunts. American College of Veterinary Surgeons. https://www.acvs.org/small-animal/portosystemic-shunts/
Konstantinidis AO, Patsikas MN, Papazoglou LG, Adamama-Moraitou KK. Congenital Portosystemic Shunts in Dogs and Cats: Treatment, Complications and Prognosis. Veterinary Sciences 2023;10(5):346. https://www.mdpi.com/2306-7381/10/5/346
Serrano G, Charalambous M, Devriendt N, de Rooster H, Mortier F, Paepe D. Treatment of congenital extrahepatic portosystemic shunts in dogs: a systematic review and meta-analysis. Journal of Veterinary Internal Medicine 2019;33(5):1865-1879. https://pmc.ncbi.nlm.nih.gov/articles/PMC6766526/
Fryer KJ, Levine JM, Peycke LE, Thompson JA, Cohen ND. Incidence of postoperative seizures with and without levetiracetam pretreatment in dogs undergoing portosystemic shunt attenuation. Journal of Veterinary Internal Medicine 2011;25(6):1379-1384. doi:10.1111/j.1939-1676.2011.00819.x
Mullins RA, Sanchez Villamil C, de Rooster H, et al. Effect of prophylactic treatment with levetiracetam on the incidence of postattenuation seizures in dogs undergoing surgical management of single congenital extrahepatic portosystemic shunts. Veterinary Surgery 2019;48(2):164-172. doi:10.1111/vsu.13141
RVC VetCompass. Yorkshire Terriers under primary veterinary care in the UK – Demography and disorders. PLOS ONE 2024. figshare dataset identifier: 25573914. https://figshare.com/articles/dataset/Yorkshire_Terriers_under_primary_veterinary_care_in_the_UK_Demography_and_disorders/25573914
Merck Veterinary Manual. Congenital and Acquired Portosystemic Shunts. https://www.merckvetmanual.com/digestive-system/hepatic-diseases-of-small-animals/acquired-portosystemic-shunts-in-small-animals
VCA Hospitals. Portosystemic Shunts in Dogs. https://vcahospitals.com/know-your-pet/portosystemic-shunt-in-dogs
VIN Veterinary Partner. Portosystemic Shunts (Liver Shunts) in Dogs and Cats. https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=254092&id=4952622

Vet Med Guide

Portosystemic Shunt (Liver Shunt) in Dogs: Bile Acids and Surgery Decisions